CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
November 10, 2022 17:40 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Announces Poster Presentation on CTX110® at the American Society of Hematology (ASH) 2022 Annual Meeting
November 03, 2022 09:06 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
November 01, 2022 16:01 ET
|
CRISPR Therapeutics AG
-Exagamglogene autotemcel (exa-cel), formerly known as CTX001™ submission to the U.S. Food and Drug Administration (FDA) for rolling review expected to begin in November, with completion of the U.S....
CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer
October 27, 2022 08:30 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Oct. 27, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
October 05, 2022 08:05 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy
September 29, 2022 08:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Sept. 29, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)
September 28, 2022 08:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
August 31, 2022 08:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
August 08, 2022 08:00 ET
|
CRISPR Therapeutics AG
-CLIMB-111 and CLIMB-121 fully enrolled; completed regulatory discussions for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, with the European Medicines Agency (EMA) and the Medicines...
CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress
June 11, 2022 11:00 ET
|
CRISPR Therapeutics AG
-70% overall response rate (ORR) and 30% complete response (CR) rate in peripheral T-cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) at Dose Level 3 (DL3) and above; clinical benefit for 90%...